All In Biotech

Drug Trial Radar · NCT04855591

A Trial of SHR-1703 in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, PK, PD and Immunogenicity of Single Subcutaneous Administered SHR-1703 in Healthy Caucasian Subjects

Last checked: Nov 19, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Jun 14, 2021

Primary completion

Sep 13, 2021

Study completion Nov 18, 2021

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.

Conditions

  • Asthma

Interventions

  • SHR-1703Drug

    SHR-1703 will be administered subcutaneously

  • PlaceboDrug

    Placebo of SHR-1703 will be administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Start of Treatment to end of study (approximately 34 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.